Alpha-1 Antitrypsin Deficiency Market to expand at a 12.8% value CAGR by 2033

Posted by Ganesh Shinde on February 20th, 2023

A recently published study by FMI expects the global Alpha-1 Antitrypsin Deficiency Market to augment at a 12.8% CAGR from 2023 to 2033. By the end of the said assessment period, a valuation of US$ 10 Billion is expected for the market.

Technological improvements, increased R&D spending, and the increasing prevalence of target illnesses are the primary drivers driving market growth.

Research and development (R&D) investments are also predicted to have a substantial impact on the industry. Several firms are attempting to construct a transformative portfolio through in-house capabilities and expanding those skills through strategic alliances, growth of R&D operations, and prospective licensing, merger, and acquisition activities.

Key Takeaways from the Market Study

• FMI projects the global alpha-1 antitrypsin deficiency market to expand at a 12.8% value CAGR by 2033
• The global Alpha-1 Antitrypsin Deficiency market is estimated at a market value of US$ 3 Billion
• The global Alpha-1 Antitrypsin Deficiency market is expected to garner a market value of US$ 10 Billion
• As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 12% in the assessment period 2023 to 2033.
• North America is expected to grow at a CAGR of 12.7% in the assessment period 2023 to 2033.
• Europe is expected to grow at a CAGR of 12.3% in the assessment period 2023 to 2033.

Market Competition

To address the present patient pool's requests and counter the therapeutic market's unmet needs, drug developers are increasingly moving their focus to alpha-1 antitrypsin deficiency (AATD).

Many novel medicines are being developed by several businesses, including ARO-AAT (Arrowhead Pharmaceutical), Alvelestat (Mereo Biopharma), and Inhaled AAT (Kamada).

ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously given drug that lowers hepatic synthesis of the mutant AAT protein by knocking down the alpha-1 antitrypsin (AAT) gene transcript. The business is now undertaking Phase II clinical studies to assess the drug's safety, tolerability, and pharmacodynamic impact in AATD patients. Key players in the Alpha-1 Antitrypsin Deficiency (A1ATD) market are:

• Pfizer
• Baxter
• AstraZeneca
• Grifols
• Teva Pharmaceutical Industries
• BoehringerIngelheim
• Kamada Ltd
• GlaxoSmithKline
•  CSL Behring
• LFB Biomedicaments

Know More About Report@ https://www.futuremarketinsights.com/reports/alpha-1-antitrypsin-deficiency-market

Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey

By Product Type:

• Augmentation Therapy
• Bronchodilators
• Corticosteroids
• Oxygen Therapy

By Application:

• Hospitals
• Specialty Clinics
• Pharmacies